MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

23.47 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents. 
Via Stocktwits
Topics Bankruptcy Fraud Intellectual Property
News headline image
Asset Manager Exits Shares of Hims & Hers Health ↗
Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗
Via MarketBeat
News headline image
Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026
As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a... 
Via Finterra
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday. 
Via Stocktwits
Topics Intellectual Property Lawsuit
From Red to Green: How Trump's Iran Endgame Sparked a Wall Street Comeback ↗
Via Chartmill
Topics Government
News headline image
HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗
Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal ↗
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile. 
Via The Motley Fool
Topics Intellectual Property Lawsuit Stocks
Top stock movements in today's session. ↗
Via Chartmill
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
The Great 2026 Pivot: Tangible Assets Surge as Tech Giants Falter in Massive Sector Rotation
The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗
Hims & Hers stock traded more than 40% higher after the deal was announced. 
Via The Motley Fool
Topics Lawsuit
News headline image
Hims & Hers Stock Pops 40%: Everything You Need to Know ↗
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why Hims & Hers Health (HIMS) Stock Is Up Today
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration wi... 
Via StockStory
Topics Economy Lawsuit Stocks
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine
Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most... 
Via Finterra
Topics Artificial Intelligence Economy
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Oil Shock Sends Nasdaq, S&P 500 Futures Lower: Why USO, INDO, HIMS, NVDA Are On Traders' Radar Today ↗
Data from Stocktwits showed that retail sentiment on SPY and QQQ remains ‘bearish.’ 
Via Stocktwits
Topics ETFs Economy Government
News headline image
HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗
Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗
According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare. 
Via Stocktwits
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Tariffs News & Market Chaos ↗
President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown ↗
The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories. 
Via Stocktwits
Topics Earnings Lawsuit
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗
The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro. 
Via Stocktwits
Topics Lawsuit
News headline image
Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances ↗
The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale. 
Via Stocktwits
Topics Earnings Supply Chain
News headline image
What's Behind The Jump In Hims & Hers Health Stock? ↗
Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a... 
Via Benzinga
News headline image
Unexpected Stock Picks and Looking to the Future ↗
Why does the shortest month of the year sometimes feel like the longest? 
Via The Motley Fool
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
The stock is down big of late, but the business is by no means doomed. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story